Compare Nanalysis Scientific Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 17 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.01
-37.86%
1.24
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Dec 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-53.33%
0%
-53.33%
6 Months
-50.0%
0%
-50.0%
1 Year
-69.57%
0%
-69.57%
2 Years
-73.08%
0%
-73.08%
3 Years
-86.67%
0%
-86.67%
4 Years
-81.58%
0%
-81.58%
5 Years
-68.18%
0%
-68.18%
Nanalysis Scientific Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.57%
EBIT Growth (5y)
-15.59%
EBIT to Interest (avg)
-6.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.99
Sales to Capital Employed (avg)
1.14
Tax Ratio
0.20%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.72
EV to EBIT
-9.81
EV to EBITDA
36.74
EV to Capital Employed
1.28
EV to Sales
0.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-13.08%
ROE (Latest)
-47.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
10.70
12.30
-13.01%
Operating Profit (PBDIT) excl Other Income
0.90
1.50
-40.00%
Interest
0.40
0.30
33.33%
Exceptional Items
-0.50
-7.00
92.86%
Consolidate Net Profit
-0.70
-7.50
90.67%
Operating Profit Margin (Excl OI)
29.20%
27.30%
0.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -13.01% vs 25.51% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 90.67% vs -257.14% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
40.10
45.50
-11.87%
Operating Profit (PBDIT) excl Other Income
-0.30
1.20
-125.00%
Interest
1.40
1.30
7.69%
Exceptional Items
-0.60
-7.60
92.11%
Consolidate Net Profit
-5.70
-13.60
58.09%
Operating Profit Margin (Excl OI)
-93.80%
-75.70%
-1.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -11.87% vs 59.65% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 58.09% vs 19.05% in Dec 2024
About Nanalysis Scientific Corp. 
Nanalysis Scientific Corp.
Pharmaceuticals & Biotechnology
Nanalysis Scientific Corp., formerly Canvass Ventures Ltd., is a Canada-based company that is engaged in the business of developing, manufacturing and selling portable nuclear magnetic resonance (NMR) spectrometers for the laboratory instrumentation market. The NMReady-60 is the fully-featured portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The NMReady-60 family of NMR spectrometers are used by chemical professionals in several industries including in oil and gas, chemical, pharma, biotech, food processing and also by the government and university labs.






